i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists

Matthew G. Romei,Brandon Leonard, Zachary B. Katz,Daniel Le,Yanli Yang,Eric S. Day, Christopher W. Koo,Preeti Sharma, Jack Bevers III, Ingrid Kim, Huiguang Dai, Farzam Farahi,May Lin,Andrey S. Shaw,Gerald Nakamura,Jonathan T. Sockolosky,Greg A. Lazar

Nature Communications(2024)

引用 0|浏览3
暂无评分
摘要
The ability to leverage antibodies to agonize disease relevant biological pathways has tremendous potential for clinical investigation. Yet while antibodies have been successful as antagonists, immune mediators, and targeting agents, they are not readily effective at recapitulating the biology of natural ligands. Among the important determinants of antibody agonist activity is the geometry of target receptor engagement. Here, we describe an engineering approach inspired by a naturally occurring Fab-Fab homotypic interaction that constrains IgG in a unique i-shaped conformation. i-shaped antibody (iAb) engineering enables potent intrinsic agonism of five tumor necrosis factor receptor superfamily (TNFRSF) targets. When applied to bispecific antibodies against the heterodimeric IL-2 receptor pair, constrained bispecific IgG formats recapitulate IL-2 agonist activity. iAb engineering provides a tool to tune agonist antibody function and this work provides a framework for the development of intrinsic antibody agonists with the potential for generalization across broad receptor classes.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要